ClinicalTrials.gg
Active, not recruitingNCT07008729RETENTIONUpdated Oct 30, 2026

Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

An interventional study of Heart monitoring tools (data revision) and Control (Standard treatment) in Chronic Heart Failure, Heart Transplant Recipient and Left Ventricular Assist Device, sponsored by Puerta de Hierro University Hospital. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Puerta de Hierro University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Apr 2024, registered May 2025).
Updated Oct 30, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 105 studies in Heart Failure with a site in Greece — 21 open to participants now, 27 under way, 14 of them phase 3. Heart Failure · Greece.

Enrollment
41st of 84
390 · median 367
Started
2024
with 11 others
No phase
27 of 105
5 open now
Primary completion
2026-10
later than 7 of 26 live
Registered
98th of 105
by date

Among the 105 studies in Heart Failure with a site in Greece, this one is the 41st largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2024, is one of 27 with no phase, reaches primary completion later than 7 of the 26 other live ones, and was the 98th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

21 of the 105 studies in Heart Failure with a site in Greece are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Heart Failure with a site in Greece, or all of them as a file.
02

Study summary

The goal of this study is to create a digital platform for managing patients with chronic heart failure, those with long-term ventricular assistance, or heart transplant recipients. This platform aims to help doctors make clinical decisions and change treatments based on continuous monitoring and the collection of medical, clinical, physiological, behavioral, psychosocial, and real-world data from these patients.

The ultimate goal is to reduce mortality and hospitalization rates for this group of patients while improving their quality of life, safety, and well-being.

To do this, participants will be divided into two groups:

  • Intervention Group: The data collected by the platform will be available to their treating doctors.
  • Control Group: Doctors will not have access to the data.

All participating patients will receive a set of devices and sensors to collect data such as vital signs, physical activity, sleep quality, psychological and nutritional status, and environmental data. All this information will be gathered through a mobile app designed for the study.

The follow-up will last for 18 months, during which there will be 4 in-person medical visits (spaced 4 months apart). Participation in the study won't affect patients' scheduled medical visits related to their illness or their usual treatment.

Read the detailed description

Specifically, the devices that will be given to the patients and their required use will be as follows:

A Smartphone: This will have the app with the platform designed for the study. The patient must interact with it daily to enter data.

A Blood Pressure Monitor: The patient will need to take their blood pressure every day and send it via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).

An Oxygen Saturation Monitor: The patient will need to check their oxygen levels daily and send the data via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).

A Scale: The patient will need to weigh themselves daily and transmit the data via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).

A Smartwatch: The patient must send data on their physical activity and sleep daily via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).

Home Humidity and Temperature Sensors and a Home Gateway Device (Raspberry Pi): The patient will need to connect this last device to their home internet network. The connection setup will be done by the study team before giving it to the patients.

There are other data and information that the patient must manually enter into the app, such as daily body temperature, symptoms they experience (like increased fatigue or shortness of breath), or data on the functioning of the long-term ventricular assistance (controller parameters or alarm presence). Additionally, the app will show the patient's current medication, which they need to confirm they have taken correctly.

The scheduled visits during the study will take place at the Baseline and every four months. These visits will include an in-person medical visit, an electrocardiogram, a blood test, and a 6-minute walk test. Also, at each visit, a series of questionnaires will be given to assess the patient's cognitive, nutritional, and psychological state, as well as their quality of life and that of their primary caregivers. Some visits will also include more specific cardiac tests, like an echocardiogram or a cardiopulmonary exercise test.

If during the study follow-up, the treating doctors unexpectedly discover any information that affects the patient's health or quality of life, the patient will be informed immediately, even if it is unrelated to the study's purpose.

All data recorded throughout the study will be stored anonymously by the study platform.

03

Conditions studied

  • Chronic Heart Failure
  • Heart Transplant Recipient
  • Left Ventricular Assist Device

Browse trials for

Keywords

  • Remote patient management
  • Telemonitoring
  • Chronic heart failure
  • Heart transplant
  • durable left ventricular assist device
  • hospitalisations
  • heart failure decompensation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18-75 years.
  • Ability to understand and provide consent in order to participate in the study.
  • Have a cognitive assessment score of > 22 as assessed by the (MoCA), ( adults without or with mild cognitive impairment at most).
  • Have a depression score as assessed by Personal Health Questionnaire-9 (PHQ-9) score \< 10.
  • Provide written .
  • For Heart Failure patients: 1) have a diagnosis of symptomatic heart failure (class II or III according to the Classification); 2) have echocardiographically determined (LVEF) ≤40%; 3) have been hospitalized due to cardiovascular reasons or had urgent visit to the Emergency Department due to decompensated HF that required administration of intravenous diuretics within the last 12 months before randomization (Currently hospitalized patients can be included provided they do not fulfill exclusion criterion of being currently with in-hospital administration of IV diuretics/vasoactive/inotropic drugs).
  • For patients with ventricular assist devices (VAD): have left ventricular assist device (LVAD) implanted either as destination therapy or as bridge-to-transplantation, within at least 90 days and no longer than 48 months before randomization
  • for heart transplant recipients: have been discharged following heart transplantation within at least 30 days and no longer than 36 months before study randomization.

Exclusion criteria

Exclusion Criteria:

  • Is clinically unstable at the time of randomization as defined by: administration of intravenous diuretics during the last 12 hours or intravenous vasodilators or inotropes during the last 48 hours before randomization.
  • Has acute coronary syndrome within the last 30 days before randomization.
  • Has acute inflammatory heart disease, (for instance, acute myocarditis), within 90 days prior to randomization.
  • Has a planned revascularisation, cardiac resynchronization therapy (CRT) implantation or any valvular procedures within 3 months after randomization
  • Has known current alcohol or illicit drug abuse.
  • Shows significant impairment or unwillingness to use the telemonitoring equipment (for instance, dementia, impaired self-determination, lacking ability to communicate).
  • Has any severe non-cardiovascular disease limiting to less than 1 year.
  • Is pregnant.
  • Participates currently in other telemonitoring programs/studies using smart devices
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    Intervention group

    The RETENTION platform will offer to the clinician in the experimental arm all the data gathered by the devices (smart watch, scale, oximeter, blood pressure monitor, temperature, medication adherence, weather and pollution indexes). along with artificial intelligence recommendations.

    Device: Heart monitoring tools (data revision)

  • Placebo comparator
    Control group

    Patients in the control group will be monitored but the data will not be available to the clinicians nor the artificial intelligence recommendations.

    Other: Control (Standard treatment)

Interventions

  • DeviceHeart monitoring tools (data revision)

    data collected by the devices will be reviewed by the treating physician in the intervention group

  • OtherControl (Standard treatment)

    Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations

06

What researchers measure

Primary outcomes

  1. Percentage of days lost due to unplanned cardiovascular hospitalization or all-cause death

    Percentage of follow-up days lost due to CEC-adjudicated unplanned cardiovascular hospitalization or death from any cause, from randomization through the common 12-month horizon, comparing the remote patient monitoring and interventions (RPMI) group with the remote patient monitoring and usual care (RPMUC) group. Computed as 100 x days lost / days under observation through 12 months; after death, all remaining days to the 12-month horizon are counted as lost.

    Time frame: From randomization through the common 12-month analysis horizon

Secondary outcomes

  1. Rates of all-cause mortality

    Time frame: From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months

  2. Rates of cardiovascular mortality

    Time frame: From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months

  3. Differences in time to first unplanned HF hospitalization

    Time frame: From the enrollment to the end of the follow up (18 months)]

  4. Differences in time to first unplanned cardiovascular hospitalization

    Time frame: From the enrollment to the end of the follow up (18 months)]

  5. Rate of total unplanned HF hospitalizations

    Time frame: From the enrollment to the end of the follow up (18 months)

  6. Rate of total unplanned cardiovascular hospitalizations

    Time frame: From the enrollment to the end of the follow up (18 months)

  7. Differences in days lost due to HF hospitalizations

    Time frame: From the enrollment to the end of the follow up (18 months)]

  8. Differences in the number of Smart device alarm notifications

    Time frame: From the enrollment to the end of the follow up (18 months)

  9. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    Change from baseline to the month 12 visit. KCCQ from 0-100

    Time frame: Baseline and month 12

  10. Change in the levels of NT-proBNP

    Between Baseline and last visit

    Time frame: Baseline and month 12

  11. Change in the Depression Score Patient Health Questionnaire 9 (PHQ-9)

    Between baseline and last visit

    Time frame: Baseline and month 12

  12. Change in the Heart Failure Caregiver Questionnaire (HF-CQ version 5.0)

    Between baseline and last visit

    Time frame: Baseline and month 12

  13. Difference in the rate of rejection needing treatment in heart transplant patients

    Time frame: From the enrollment to the end of the follow up (18 months)

  14. Driveline infection needing antibiotic in left ventricular assist device (LVAD) patients

    Time frame: From the enrollment to the end of the follow up (18 months)

  15. Differences in the rate of unplanned visit for heart failure requiring intravenous diuretics

    Time frame: From the enrollment to the end of the follow up (18 months)

  16. Difference in the number of visits outside the protocol

    Time frame: From the enrollment to the end of the follow up (18 months)

  17. Time to first unplanned cardiovascular hospitalization or all-cause death

    Time from randomization to the first occurrence of unplanned cardiovascular hospitalization or death from any cause, whichever occurs first, comparing RPMI vs RPMUC.

    Time frame: Up to 18 months (full individual follow-up); also analysed with administrative censoring at 12 months

07

Study locations

6 sites
08

References and documents

Publications

  • Scott IA, Scuffham P, Gupta D, Harch TM, Borchi J, Richards B. Going digital: a narrative overview of the effects, quality and utility of mobile apps in chronic disease self-management. Aust Health Rev. 2020 Feb;44(1):62-82. doi: 10.1071/AH18064. PubMed 30419185 ↗
  • Ski CF, Thompson DR, Brunner-La Rocca HP. Putting AI at the centre of heart failure care. ESC Heart Fail. 2020 Oct;7(5):3257-3258. doi: 10.1002/ehf2.12813. Epub 2020 Jun 17. No abstract available. PubMed 32558251 ↗
  • McConnell MV, Turakhia MP, Harrington RA, King AC, Ashley EA. Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation: Moving Hearts. J Am Coll Cardiol. 2018 Jun 12;71(23):2691-2701. doi: 10.1016/j.jacc.2018.04.030. PubMed 29880130 ↗
  • Dorsey ER, Yvonne Chan YF, McConnell MV, Shaw SY, Trister AD, Friend SH. The Use of Smartphones for Health Research. Acad Med. 2017 Feb;92(2):157-160. doi: 10.1097/ACM.0000000000001205. PubMed 27119325 ↗
  • Liu L, Stroulia E, Nikolaidis I, Miguel-Cruz A, Rios Rincon A. Smart homes and home health monitoring technologies for older adults: A systematic review. Int J Med Inform. 2016 Jul;91:44-59. doi: 10.1016/j.ijmedinf.2016.04.007. Epub 2016 Apr 19. PubMed 27185508 ↗
  • Goswami R. The current state of artificial intelligence in cardiac transplantation. Curr Opin Organ Transplant. 2021 Jun 1;26(3):296-301. doi: 10.1097/MOT.0000000000000875. PubMed 33938466 ↗
  • Shahbazi F, Asl BM. Generalized discriminant analysis for congestive heart failure risk assessment based on long-term heart rate variability. Comput Methods Programs Biomed. 2015 Nov;122(2):191-8. doi: 10.1016/j.cmpb.2015.08.007. Epub 2015 Aug 24. PubMed 26344584 ↗
  • Tripoliti EE, Papadopoulos TG, Karanasiou GS, Naka KK, Fotiadis DI. Heart Failure: Diagnosis, Severity Estimation and Prediction of Adverse Events Through Machine Learning Techniques. Comput Struct Biotechnol J. 2016 Nov 17;15:26-47. doi: 10.1016/j.csbj.2016.11.001. eCollection 2017. PubMed 27942354 ↗
  • Bennett MK, Shao M, Gorodeski EZ. Home monitoring of heart failure patients at risk for hospital readmission using a novel under-the-mattress piezoelectric sensor: A preliminary single centre experience. J Telemed Telecare. 2017 Jan;23(1):60-67. doi: 10.1177/1357633X15618810. Epub 2016 Jul 9. PubMed 26670209 ↗
  • Yun JE, Park JE, Park HY, Lee HY, Park DA. Comparative Effectiveness of Telemonitoring Versus Usual Care for Heart Failure: A Systematic Review and Meta-analysis. J Card Fail. 2018 Jan;24(1):19-28. doi: 10.1016/j.cardfail.2017.09.006. Epub 2017 Sep 20. PubMed 28939459 ↗
  • Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2. PubMed 28785469 ↗
  • Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, De Marco T, Escarce JJ, Evangelista LS, Hanna B, Ganiats TG, Greenberg BH, Greenfield S, Kaplan SH, Kimchi A, Liu H, Lombardo D, Mangione CM, Sadeghi B, Sadeghi B, Sarrafzadeh M, Tong K, Fonarow GC; Better Effectiveness After Transition-Heart Failure (BEAT-HF) Research Group. Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial. JAMA Intern Med. 2016 Mar;176(3):310-8. doi: 10.1001/jamainternmed.2015.7712. PubMed 26857383 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 30 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 6, 2025
StartActual
Apr 24, 2024
Primary completionEst.
Oct 31, 2026was Aug 2026
CompletionEst.
Nov 30, 2026was Aug 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Oct 31, 2026
Oct 30, 2026
Study completion
Aug 31, 2026→Nov 30, 2026
Oct 30, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedDifference inPercentage of days lost due to unplanned cardiovascular hospitalizationshospitalization or all-cause death between groupsTime frame: From the enrollment to the end of the follow up (18 months) → From randomization through the common 12-month analysis horizon
  • RemovedDifferences in the rates of occurrence of death or unplanned hospitalization/ambulatory administration of intravenous (iv) diuretics, iv antibiotics or iv steroidsTime frame: From the enrollment to the end of the follow up (18 months)
Oct 30, 2026
Secondary outcomes
6 time frame changed, 1 added, 1 description edited
What changed in the outcomes
  • AddedTime to first unplanned cardiovascular hospitalization or all-cause deathTime frame: Up to 18 months (full individual follow-up); also analysed with administrative censoring at 12 months
  • Time frameRates of all-cause mortalityFrom the enrollment to the end of the follow up (18 months) → From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months
  • Time frameRates of cardiovascular mortalityFrom the enrollment to the end of the follow up (18 months)] → From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months
  • Time frameChange in Kansas City Cardiomyopathy Questionnaire (KCCQ) scoreFrom the enrollment to the end of the follow up (18 months) → Baseline and month 12
  • Time frameChange in the levels of NT-proBNPFrom the enrollment to the end of the follow up (18 months) → Baseline and month 12
  • Time frameChange in the Depression Score Patient Health Questionnaire 9 (PHQ-9)From the enrollment to the end of the follow up (18 months) → Baseline and month 12
  • Time frameChange in the Heart Failure Caregiver Questionnaire (HF-CQ version 5.0)From the enrollment to the end of the follow up (18 months)] → Baseline and month 12
  • DescriptionChange in Kansas City Cardiomyopathy Questionnaire (KCCQ) score: how it is measured was reworded
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Aug 31, 2026→Oct 31, 2026
    Study completion Aug 31, 2026→Nov 30, 2026
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedDifference inPercentage of days lost due to unplanned cardiovascular hospitalizationshospitalization or all-cause death between groupsTime frame: From the enrollment to the end of the follow up (18 months) → From randomization through the common 12-month analysis horizon
    • RemovedDifferences in the rates of occurrence of death or unplanned hospitalization/ambulatory administration of intravenous (iv) diuretics, iv antibiotics or iv steroidsTime frame: From the enrollment to the end of the follow up (18 months)
    Secondary outcomes 6 time frame changed, 1 added, 1 description edited
    What changed in the outcomes
    • AddedTime to first unplanned cardiovascular hospitalization or all-cause deathTime frame: Up to 18 months (full individual follow-up); also analysed with administrative censoring at 12 months
    • Time frameRates of all-cause mortalityFrom the enrollment to the end of the follow up (18 months) → From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months
    • Time frameRates of cardiovascular mortalityFrom the enrollment to the end of the follow up (18 months)] → From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months
    • Time frameChange in Kansas City Cardiomyopathy Questionnaire (KCCQ) scoreFrom the enrollment to the end of the follow up (18 months) → Baseline and month 12
    • Time frameChange in the levels of NT-proBNPFrom the enrollment to the end of the follow up (18 months) → Baseline and month 12
    • Time frameChange in the Depression Score Patient Health Questionnaire 9 (PHQ-9)From the enrollment to the end of the follow up (18 months) → Baseline and month 12
    • Time frameChange in the Heart Failure Caregiver Questionnaire (HF-CQ version 5.0)From the enrollment to the end of the follow up (18 months)] → Baseline and month 12
    • DescriptionChange in Kansas City Cardiomyopathy Questionnaire (KCCQ) score: how it is measured was reworded
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07008729
Lead sponsor
Puerta de Hierro University Hospital
Collaborators
Hannover Medical School, Attikon Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Onassis Cardiac Surgery Centre, Hospital Universitario Ramon y Cajal
Responsible party
Mercedes Rivas-Lasarte (Principal Investigator, MD PHD, Cardiology Department, Puerta de Hierro University Hospital) — Principal investigator
First posted
Jun 6, 2025
Start date
Apr 24, 2024
Primary completion
Oct 31, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 30, 2026

Study contacts

Maria Haritou, PhD
study chair · ICCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion